DaVita's Q3 Net Income Plunges 30% Amid Rising Costs, Debt

TL;DR

**DaVita's Q3 net income cratered 30% despite revenue gains, signaling deep operational cost issues and a debt burden that's eating into profits, making it a risky bet right now.**

AI Summary

DaVita Inc. reported a decline in net income attributable to DaVita Inc. for both the three and nine months ended September 30, 2025. For the three months, net income decreased by 30% to $150.3 million from $214.7 million in the prior year. For the nine months, net income fell by 24.3% to $512.6 million from $677.0 million. Total revenues, however, saw an increase, reaching $3.42 billion for the three months, up 4.8% from $3.26 billion, and $10.02 billion for the nine months, up 5.3% from $9.52 billion. This revenue growth was primarily driven by a 5.1% increase in dialysis patient service revenues to $3.298 billion for the three months and a 5.1% increase to $9.608 billion for the nine months. Operating expenses rose significantly, with patient care costs increasing by 8.4% to $2.333 billion for the three months and 7.2% to $6.834 billion for the nine months. Debt expense also surged, up 11.9% to $150.6 million for the three months and 30.1% to $431.7 million for the nine months, contributing to the net income decline. The company also saw a substantial increase in treasury stock purchases, with a balance of $(2.905) billion as of September 30, 2025, compared to $(1.389) billion at December 31, 2024.

Why It Matters

DaVita's significant drop in net income, despite revenue growth, signals increasing operational pressures and higher debt servicing costs, which could impact investor confidence. The substantial increase in patient care costs and debt expense suggests challenges in managing expenses within the competitive healthcare services sector, particularly against rivals like Fresenius Medical Care. For employees, this could imply tighter cost controls, while customers might see continued focus on efficiency. The aggressive treasury stock purchases, totaling over $1.4 billion in the nine months, indicate a strong commitment to shareholder returns, but this strategy is occurring alongside a deteriorating net income, raising questions about long-term financial health and capital allocation efficiency.

Risk Assessment

Risk Level: high — The risk level is high due to a 30% decrease in net income attributable to DaVita Inc. for the three months ended September 30, 2025, falling to $150.3 million from $214.7 million in the prior year. This decline is exacerbated by a 30.1% increase in debt expense to $431.7 million for the nine months, alongside a 7.2% rise in patient care costs to $6.834 billion, indicating significant operational and financial leverage risks.

Analyst Insight

Investors should exercise caution and thoroughly evaluate DaVita's ability to control escalating patient care costs and manage its growing debt burden. Consider holding off on new investments until there's clear evidence of improved cost management and a reversal in the declining net income trend, despite the revenue growth.

Financial Highlights

revenue

$10.02B

net Income

$512.6M

revenue Growth

+5.3%

Revenue Breakdown

Key Numbers

• $150.3M — Net income attributable to DaVita Inc. (Decreased by 30% for the three months ended September 30, 2025, from $214.7 million in the prior year.)
• $512.6M — Net income attributable to DaVita Inc. (Decreased by 24.3% for the nine months ended September 30, 2025, from $677.0 million in the prior year.)
• $3.42B — Total revenues (Increased by 4.8% for the three months ended September 30, 2025, from $3.26 billion.)
• $10.02B — Total revenues (Increased by 5.3% for the nine months ended September 30, 2025, from $9.52 billion.)
• $2.333B — Patient care costs (Increased by 8.4% for the three months ended September 30, 2025, from $2.152 billion.)
• $6.834B — Patient care costs (Increased by 7.2% for the nine months ended September 30, 2025, from $6.373 billion.)
• $150.6M — Debt expense (Increased by 11.9% for the three months ended September 30, 2025, from $134.6 million.)
• $431.7M — Debt expense (Increased by 30.1% for the nine months ended September 30, 2025, from $331.7 million.)
• $2.905B — Treasury stock (Balance as of September 30, 2025, significantly higher than $1.389 billion at December 31, 2024.)
• 70.6M — Common stock shares outstanding (As of October 28, 2025.)

Key Players & Entities

• DAVITA INC. (company) — registrant
• Bloomberg (company) — publisher
• SEC (regulator) — filing authority
• $150,332 (dollar_amount) — Net income attributable to DaVita Inc. for Q3 2025
• $214,688 (dollar_amount) — Net income attributable to DaVita Inc. for Q3 2024
• $3,420,227 (dollar_amount) — Total revenues for Q3 2025
• $2,332,759 (dollar_amount) — Patient care costs for Q3 2025
• $150,557 (dollar_amount) — Debt expense for Q3 2025
• $2,904,806 (dollar_amount) — Treasury stock balance as of September 30, 2025
• Fresenius Medical Care (company) — competitor

FAQ

Risk Factors

• Increased Debt Expense [high — financial]: Debt expense surged by 11.9% to $150.6 million for the three months and 30.1% to $431.7 million for the nine months ended September 30, 2025. This significant increase directly impacts profitability, contributing to the decline in net income.
• Rising Patient Care Costs [medium — operational]: Patient care costs increased by 8.4% to $2.333 billion for the three months and 7.2% to $6.834 billion for the nine months ended September 30, 2025. This rise in operational expenses outpaced revenue growth in percentage terms for the three-month period, pressuring margins.
• Aggressive Share Buybacks [medium — financial]: The company significantly increased treasury stock purchases, with a balance of $(2.905) billion as of September 30, 2025, up from $(1.389) billion at December 31, 2024. While intended to return value, this large outlay could impact liquidity and future investment capacity.
• Healthcare Regulatory Environment [high — regulatory]: DaVita operates in a highly regulated healthcare industry. Changes in government policies, reimbursement rates (e.g., Medicare/Medicaid), and compliance requirements can significantly impact financial performance and operational strategies.

Industry Context

The dialysis services industry is characterized by high patient acuity, significant regulatory oversight, and a concentrated payer mix (Medicare and private insurance). Competition exists from other large providers and smaller independent centers. Trends include increasing patient populations due to chronic diseases like diabetes and hypertension, and evolving reimbursement models.

Regulatory Implications

DaVita is subject to extensive federal and state regulations governing healthcare providers, including those related to patient care quality, billing and coding practices, and Stark Law/Anti-Kickback statutes. Changes in Medicare reimbursement rates or new compliance mandates could materially affect profitability.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-09-30: Quarterly Financial Reporting — DaVita reported a 30% decrease in net income for the three months and a 24.3% decrease for the nine months, despite revenue growth, highlighting margin pressures.
• 2025-09-30: Balance Sheet Date — Indicates a substantial increase in treasury stock purchases to $(2.905) billion, signaling a significant capital allocation strategy.

Glossary

Treasury Stock

Shares of a company's own stock that have been repurchased by the company. These shares are no longer outstanding and do not carry voting rights. (A significant increase in treasury stock balance indicates substantial capital deployment towards share buybacks, impacting cash and equity.)

Patient Care Costs

Expenses directly related to providing healthcare services to patients, including labor, supplies, and medical equipment. (A key component of operating expenses; rising patient care costs are pressuring DaVita's profitability.)

Debt Expense

The cost incurred by a company for borrowing money, typically including interest payments on loans and bonds. (An increase in debt expense directly reduces net income and can signal higher borrowing costs or increased leverage.)

Year-Over-Year Comparison

Compared to the prior year, DaVita Inc. reported increased total revenues for both the three and nine months ended September 30, 2025, up 4.8% and 5.3% respectively. However, net income attributable to DaVita Inc. saw a significant decline of 30% for the three months and 24.3% for the nine months. This divergence is driven by a substantial increase in operating expenses, notably patient care costs (up 8.4% and 7.2%) and a sharp rise in debt expense (up 11.9% and 30.1%), which have outpaced revenue growth and eroded profitability.

Key Financial Figures

• $0.001 — nge on which registered: Common Stock, $0.001 par value DVA NYSE Indicate by check

Filing Documents

• dva-20250930.htm (10-Q) — 1939KB
• dva-93025ex31110xq.htm (EX-31.1) — 9KB
• dva-93025ex31210xq.htm (EX-31.2) — 9KB
• dva-93025ex32110xq.htm (EX-32.1) — 5KB
• dva-93025ex32210xq.htm (EX-32.2) — 5KB
• dva-20250930_g1.jpg (GRAPHIC) — 32KB
• 0000927066-25-000165.txt ( ) — 9067KB
• dva-20250930.xsd (EX-101.SCH) — 52KB
• dva-20250930_cal.xml (EX-101.CAL) — 84KB
• dva-20250930_def.xml (EX-101.DEF) — 282KB
• dva-20250930_lab.xml (EX-101.LAB) — 711KB
• dva-20250930_pre.xml (EX-101.PRE) — 499KB
• dva-20250930_htm.xml (XML) — 1366KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements: Consolidated Statements of Income for the three and nine months ended September 30, 2025 and September 30, 2024 1 Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2025 and September 30, 2024 2 Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Consolidated Statements of Cash Flow for the nine months ended September 30, 2025 and September 30, 2024 4 Consolidated Statements of Equity for the three and nine months ended September 30, 2025 and September 30, 2024 5 Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 23

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 39

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 40

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 40

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 40

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 41

Other Information

Item 5. Other Information 41

Exhibits

Item 6. Exhibits 42 Signature 43 i DAVITA INC. CONSOLIDATED STATEMENTS OF INCOME (unaudited) (dollars and shares in thousands, except per share data) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Dialysis patient service revenues $ 3,298,090 $ 3,138,561 $ 9,607,954 $ 9,141,195 Other revenues 122,137 125,029 415,328 379,672 Total revenues 3,420,227 3,263,590 10,023,282 9,520,867 Operating expenses: Patient care costs 2,332,759 2,151,875 6,833,959 6,373,150 General and administrative 414,373 393,534 1,201,268 1,123,859 Depreciation and amortization 177,490 187,014 528,645 549,758 Equity investment income, net ( 10,162 ) ( 3,711 ) ( 23,135 ) ( 15,874 ) Gain on changes in ownership interests — — — ( 35,147 ) Total operating expenses 2,914,460 2,728,712 8,540,737 7,995,746 Operating income 505,767 534,878 1,482,545 1,525,121 Debt expense ( 150,557 ) ( 134,583 ) ( 431,674 ) ( 331,748 ) Debt extinguishment and modification costs ( 5,150 ) ( 10,081 ) ( 5,150 ) ( 19,813 ) Other loss, net ( 41,257 ) ( 16,780 ) ( 81,657 ) ( 56,900 ) Income before income taxes 308,803 373,434 964,064 1,116,660 Income tax expense 68,554 77,674 216,379 215,168 Net income 240,249 295,760 747,685 901,492 Less: Net income attributable to noncontrolling interests ( 89,917 ) ( 81,072 ) ( 235,099 ) ( 224,479 ) Net income attributable to DaVita Inc. $ 150,332 $ 214,688 $ 512,586 $ 677,013 Earnings per share attributable to DaVita Inc.: Basic net income $ 2.09 $ 2.56 $ 6.77 $ 7.86 Diluted net income $ 2.04 $ 2.50 $ 6.62 $ 7.66 Weighted average shares for earnings per share: Basic shares 72,075 83,721 75,768 86,123 Diluted shares 73,769 85,795 77,442 88,422 See notes to condensed consolidated financial statements. 1 DAVITA INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (dollars in thousands) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Net income $ 240,2